Two malaria vaccines are now approved for use in children living in areas where the disease is common, both targeting the same vulnerable moment in the parasite’s life cycle: the brief window after an infected mosquito bite when the parasite travels to the liver. The first, RTS,S (sold as Mosquirix), was recommended by the World Health Organization in 2021 after roughly 60 years of malaria vaccine development. The second, R21/Matrix-M, followed in 2023 with higher efficacy numbers in trials. Both are designed for young children in sub-Saharan Africa and other endemic regions, the group that bears the heaviest burden of malaria illness and death.
What the Vaccines Actually Target
The malaria parasite, Plasmodium falciparum, wears a protein coat called circumsporozoite protein (CSP) on its surface during the sporozoite stage, the form injected into your bloodstream by a mosquito. Both approved vaccines train the immune system to recognize and attack CSP before the parasite can reach the liver and begin multiplying. If the immune response catches enough sporozoites at this stage, the infection never progresses to the blood stage that causes fever, anemia, and potentially fatal complications.
RTS,S was built using a clever trick borrowed from hepatitis B vaccine technology. Researchers fused part of the CSP protein onto the hepatitis B surface antigen (HBsAg), creating virus-like particles that display the malaria protein in a highly repetitive pattern the immune system finds easy to recognize. The “RTS” in the name refers to the CSP repeat region and T-cell epitopes fused to the surface antigen, while the extra “S” is unfused HBsAg that spontaneously incorporates into the particle. The vaccine is paired with a potent adjuvant called AS01 that amplifies the immune response.1PubMed Central. RTS,S/AS01 vaccine (Mosquirix™): an overview
R21/Matrix-M, developed at Oxford, uses the same general concept but refines it. The key change is eliminating the excess unfused HBsAg that makes up a large proportion of RTS,S particles. Without that extra filler, the R21 particle packs more CSP onto its surface: roughly 25 micrograms of CSP in each dose compared to about 10 micrograms in RTS,S. R21 also swaps in a different adjuvant, Novavax’s Matrix-M, a saponin-based compound that appears to boost the immune response more efficiently.2PubMed Central. Breaking the malaria barrier: the WHO-approved R21/Matrix-M vaccine and its global impact – an editorial
How Well They Work in Children
Neither vaccine prevents malaria the way the measles vaccine prevents measles. Protection is partial and fades over time. But in a disease that kills hundreds of thousands of young children each year, even partial protection translates into enormous numbers of lives saved.
RTS,S was tested in a large phase 3 trial across 11 African sites. In children aged 5 to 17 months, vaccine efficacy against clinical malaria was about 46% over 18 months after the primary three-dose series, and efficacy against severe malaria was around 34%.3PLoS Medicine. Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites Earlier results from the same trial, looking at the first 14 months, had shown efficacy of about 50% against clinical malaria and 45% against severe malaria in older children.4PubMed. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children Protection was consistently lower in younger infants (6 to 12 weeks old), where efficacy against clinical malaria was about 27%.3PLoS Medicine. Efficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites
R21/Matrix-M posted stronger numbers in its phase 3 trial. At seasonal transmission sites, where malaria comes in predictable waves, 12-month vaccine efficacy was about 75% against a first malaria episode. At sites with year-round transmission, efficacy was about 68%.5PubMed Central. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial Those are striking numbers for a disease as complex as malaria, though direct head-to-head comparisons with RTS,S are still limited, and the trial designs and follow-up periods differ in ways that make simple side-by-side ranking tricky.
Why Protection Wanes and What Boosters Do
One of the biggest practical challenges with both vaccines is that their protection drops steadily after the initial series. The antibodies the vaccines generate against CSP decline substantially within six months of vaccination and become nearly undetectable by about 21 months.6PubMed Central. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children This pattern mirrors the drop in efficacy seen in clinical trials, where protection is highest in the months immediately following vaccination and then tapers.
Booster doses help. A fourth dose of RTS,S given 18 months after the primary series partially restores protection, which is why the WHO-recommended schedule includes a booster. For R21, the recommended schedule is three primary doses followed by a booster before the next malaria season. Research into delayed and fractional booster strategies suggests that spacing doses further apart can produce more durable antibody responses. In trials of a related malaria vaccine candidate, a delayed fractional booster schedule generated antibody levels that plateaued at roughly ten times the concentration seen with the standard monthly schedule over two years.7The Journal of Clinical Investigation. Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine Whether this approach works equally well for RTS,S and R21 in real-world settings is still being studied.
Who Is Supposed to Get the Vaccine
Both vaccines are recommended for children living in moderate-to-high malaria transmission areas, starting at about five months of age. The target population is young children because they account for the vast majority of malaria deaths: kids under five have not yet built up the partial natural immunity that older children and adults gradually acquire through repeated infections.
The vaccines are not currently recommended for travelers, adults, or people in areas where malaria is rare. That is a practical decision based on where the burden is greatest and where the evidence exists. Clinical trials were conducted in African children, and the WHO recommendation reflects that evidence base. Adults who grew up in endemic areas already have some degree of natural immunity, so the calculus is different for them. Tourists heading to malaria zones still rely on preventive drugs and mosquito avoidance rather than vaccination.
Seasonal Timing and Combination With Other Prevention
In parts of West Africa where malaria transmission is concentrated in a rainy season, an especially effective strategy has emerged: giving the vaccine before the season starts and combining it with seasonal malaria chemoprevention (SMC), a regimen of antimalarial drugs given to children monthly during peak transmission. A five-year trial in Burkina Faso and Mali found that the combination of seasonal RTS,S vaccination plus SMC was far more effective than either approach alone. The combined strategy cut clinical malaria incidence to roughly 133 cases per 1,000 person-years, compared to about 313 with SMC alone and 320 with RTS,S alone. That works out to about 58–59% additional protection from combining the two.8The Lancet Infectious Diseases. Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial
This finding matters because it demonstrates that the vaccine works best not as a replacement for existing tools but as a layer on top of them. Bed nets, indoor spraying, and antimalarial drugs remain essential. Insecticide-treated bed nets alone can reduce malaria cases by about half when used consistently, and modeling suggests that if 75% of a population used them, malaria transmission could be eliminated in some settings.9PubMed Central. The impact of bed-net use on malaria prevalence The vaccine adds another tool without replacing any of the others.
Safety Profile
Both vaccines cause the kinds of side effects you would expect from any childhood immunization. Injection-site pain and fever are the most commonly reported reactions, along with irritability, drowsiness, and loss of appetite. The vast majority of these subside within a week.10PubMed Central. Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies
More serious adverse events have been tracked closely. A systematic review and meta-analysis of RTS,S trials in children aged 5 to 17 months found that serious adverse events actually occurred less frequently in the vaccine group (about 21%) than in the control group receiving a rabies vaccine (about 26%). Death rates were similar in both groups, at roughly 1.3%. The most notable safety signal with RTS,S has been febrile convulsions, which occurred at slightly higher rates in vaccinated children, though they were uncommon overall and resolved without lasting harm.11PubMed Central. Safety of RTS,S/AS01E vaccine for malaria in African children aged 5 to 17 months: A systematic review and meta-analysis of randomized controlled trials Across the broader scoping review of multiple malaria vaccine candidates, vaccine-related serious adverse events were rare, in the range of 0.1–1% of participants for RTS,S and about 4.3% for R21, mainly febrile convulsions or seizures.10PubMed Central. Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies
Getting Vaccines to Where They Are Needed
Manufacturing and delivering millions of doses across sub-Saharan Africa has been one of the hardest parts. Demand for both RTS,S and R21 far outstrips current production capacity. Countries are competing for limited supply, and Gavi, the global vaccine alliance, has had to allocate doses carefully. Cold chain requirements, the need for multiple doses per child, shortages of trained health workers, and weak monitoring systems all complicate delivery, particularly in remote rural areas where malaria is often worst.12PubMed. Challenges to malaria vaccine availability and successful implementation of malaria vaccine program in Africa Funding constraints at the national level add another layer: many endemic countries struggle to budget for acquiring, transporting, storing, and actually administering the vaccines.13PubMed. Update on malaria vaccine deployment and challenges in the field
R21 has a potential advantage here. The Serum Institute of India, the world’s largest vaccine manufacturer by volume, is producing R21 at a projected cost of a few dollars per dose, which is lower than RTS,S. Cost-effectiveness modeling for R21 estimates an incremental cost of roughly $30–34 per disability-adjusted life year averted, a figure that makes it highly cost-effective by global health standards.14The Lancet Infectious Diseases. Public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine candidate: a mathematical modelling study Earlier modeling of RTS,S pegged its cost at around $200 per DALY averted at $5 per dose, still well within the threshold considered worthwhile for low-income countries.15PubMed Central. Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries
Whether Parents Actually Want It
A vaccine that exists but sits unused helps nobody. The evidence on parental acceptance is encouraging. A meta-analysis of studies across sub-Saharan Africa found a pooled acceptance rate of about 82% among caregivers of children under five, with willingness to vaccinate at roughly 80%.16PubMed Central. Community readiness and acceptance for the implementation of the malaria vaccine among caretakers of at-risk children in sub-Saharan Africa: a systematic review and meta-analysis In Burundi, acceptance was even higher, with over 90% of surveyed caregivers saying they would accept the vaccine. Prior experience with childhood vaccination and knowledge about the malaria vaccine were strong predictors of willingness.17PubMed Central. Acceptance of a malaria vaccine among caregivers of sick children under 5 years of age in Burundi
Acceptance is not uniform, though. The lowest rate found in the meta-analysis was 53%, in the Democratic Republic of Congo, a country with some of the world’s highest malaria burden but also widespread distrust of health interventions. Vaccine hesitancy, where it exists, tends to stem from concerns about side effects, mistrust of government programs, and misinformation rather than outright opposition to the concept of a malaria vaccine. Addressing those barriers is as much a communication and trust-building challenge as a medical one.
The Parasite Diversity Problem
Both RTS,S and R21 are based on the CSP sequence of a single reference strain of P. falciparum called 3D7. But malaria parasites in the wild are genetically diverse, and the CSP protein varies from one parasite population to another. A study within the large RTS,S trial found that one-year vaccine efficacy was about 50% against parasites whose CSP matched the vaccine strain, but dropped to roughly 33% against mismatched parasites.18PubMed Central. Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
This gap is a real concern. Parasite populations in different parts of Africa carry CSP sequences that diverge from 3D7 by varying numbers of amino acid changes. Along the Zambia-DRC border, for instance, the median parasite differed from 3D7 at seven amino acid positions, which could meaningfully reduce vaccine effectiveness in that region.19Scientific Reports. RTS,S/AS01 malaria vaccine mismatch observed among Plasmodium falciparum isolates from southern and central Africa and globally Future vaccine versions may need to include longer or more diverse CSP sequences to counter this diversity.20PubMed. Genetic variations of Plasmodium falciparum circumsporozoite protein and the impact on interactions with human immunoproteins and malaria vaccine efficacy Whether R21, with its higher CSP density, performs any differently against mismatched strains is not yet well characterized in published data.
Other Vaccine Approaches in the Pipeline
RTS,S and R21 are both subunit vaccines, meaning they use a single protein fragment to provoke an immune response. Other approaches take a fundamentally different tack. The PfSPZ Vaccine, developed by Sanaria, uses whole, live, radiation-weakened sporozoites rather than a protein fragment. In a trial of Malian adults, a five-dose regimen showed about 38% efficacy at six months, dropping to 15% at 18 months by one measure, though another analytical method put it at 46–48% over both periods.21PubMed Central. A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria The whole-sporozoite approach theoretically exposes the immune system to a broader set of parasite proteins, potentially addressing the strain diversity issue, but it comes with serious practical drawbacks: the vaccine requires intravenous injection and must be stored at ultra-cold temperatures, making it difficult to scale.
A systems analysis of PfSPZ vaccination in African infants highlighted an intriguing wrinkle. Children who already had high levels of innate immune activation before vaccination, likely from prior malaria exposure, actually mounted worse protective immune responses to the vaccine. Their innate immune system produced strong antibody responses but suppressed the CD8+ T-cell responses that are thought to be most important for whole-sporozoite vaccine protection.22PubMed Central. Innate immune activation restricts priming and protective efficacy of the radiation-attenuated PfSPZ malaria vaccine This is a counterintuitive but significant finding: in the populations most exposed to malaria, the whole-sporozoite vaccine may face a biological ceiling on effectiveness that has nothing to do with dosing or logistics.
Meanwhile, monoclonal antibodies are being explored as a complementary strategy. Rather than training the body to make its own antibodies, these are lab-made antibodies injected directly. One candidate, CIS43LS, targets a conserved region of CSP and demonstrated about 80% protection from liver-stage invasion lasting four to six months in controlled infection studies.23PubMed Central. Monoclonal antibody CIS43LS sets the bar for long-acting malaria protection That is a high level of protection, but the cost and need for periodic re-injection make monoclonal antibodies better suited for specific use cases like protecting travelers or pregnant women during a single season, rather than mass childhood vaccination.
Vaccines for the Other Malaria Parasite
Everything discussed so far targets Plasmodium falciparum, the species responsible for the vast majority of malaria deaths. But Plasmodium vivax is the second most common malaria parasite, with a wider geographic range that includes parts of Asia and Latin America. Neither RTS,S nor R21 provides protection against vivax malaria.
Vivax vaccine development is years behind falciparum work. One early candidate, VMP001/AS01B, is a chimeric protein incorporating parts of the vivax CSP and was tested in a phase 1/2a trial in malaria-naive adults.24PLoS Neglected Tropical Diseases. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy More recently, a multistage vaccine using viral vectors achieved 100% sterile protection and over 95% transmission-blocking activity in a mouse model, though mouse models are a long way from field efficacy in humans.25PubMed Central. A two-dose viral-vectored Plasmodium vivax multistage vaccine confers durable protection and transmission-blockade in a pre-clinical study A vivax vaccine that also blocks transmission, preventing vaccinated people from passing the parasite to mosquitoes, would be a game-changer, but that remains a preclinical aspiration for now.
How Anti-CSP Antibodies Actually Stop the Parasite
The mechanical details of what happens after vaccination are more nuanced than just “antibodies block infection.” Using a rodent model, researchers showed that anti-CSP antibodies do not simply coat sporozoites and neutralize them instantly. Instead, the antibodies progressively hamper the parasite at multiple steps: first slowing its motility in the bloodstream, then preventing it from crossing out of the liver’s blood vessels, then blocking its invasion of liver cells, and finally killing parasites even after they have entered a cell. The whole process takes several hours of accumulated antibody activity.26eLife. Dynamics of anti-circumsporozoite antibodies neutralizing malaria sporozoites in the liver
This stepwise neutralization helps explain why antibody levels matter so much and why protection drops as antibodies wane. It is not a simple on-off switch. At high antibody concentrations, the parasite gets blocked at the earliest stages. As levels decline, sporozoites start slipping through the initial barriers, and the immune system relies on later, less reliable checkpoints. The implication for vaccine design is clear: strategies that maintain higher and more durable antibody concentrations, whether through better adjuvants, delayed boosting schedules, or periodic re-vaccination, will translate directly into longer-lasting protection.